A

new lobbying partnership aimed at preventing government drug-price intervention is unfazed by President-elect Donald Trump’s anti-pharma salvo from his first press conference on Wednesday.

The President-elect’s comments didn’t surprise Joel White, the president of Horizon Government Affairs and the new head of the Rx Value Campaign, which was formed to oppose government intervention on pharmaceutical pricing in favor of free-market solutions. The coalition’s mission was first reported in Politico earlier Wednesday morning.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.